Phase I, Open-Label, 2-Period, Single-Sequence Study to Evaluate the Mass Balance and Absorption, Disposition, Metabolism and Excretion of [14C]Enpatoran, and the Absolute Bioavailability of Enpatoran in Healthy Male Participants
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Enpatoran (Primary) ; Enpatoran (Primary) ; Enpatoran (Primary)
- Indications COVID-19 pneumonia; Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 22 Mar 2022 Status changed from recruiting to completed.
- 22 Nov 2021 Status changed from not yet recruiting to recruiting.
- 08 Nov 2021 New trial record